Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
- Conditions
- Gastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Krankenhaus Nordwest
- Target Recruit Count
- 200
- Registration Number
- NCT04447352
- Locations
- 🇩🇪
Uniklinik RWTH Aachen, AöR, Medizinische Klinik III, Studienzentrum Viszeralmedizin, Aachen, Germany
🇩🇪Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany, Frankfurt, Germany
🇩🇪Universitätsklinikum, Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie, Dresden, Germany
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: Docetaxel, nedaplatin, fluorouracilDrug: Docetaxel, cisplatin, fluorouracilDrug: NedaplatinDrug: CisplatinRadiation: Intensity modulated-radiotherapy
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- Target Recruit Count
- 352
- Registration Number
- NCT04437329
- Locations
- 🇨🇳
Department of radiotherapy(Section 5),Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
- Conditions
- Nasopharyngeal CarcinomaNutrition Therapy
- Interventions
- Other: Standardized nutrition therapyRadiation: Intensity Modulated Radiation TherapyDrug: Cisplatin
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 266
- Registration Number
- NCT04436965
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
- Conditions
- Vulvar CancerVulvar Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT04430699
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-04-04
- Target Recruit Count
- 4
- Registration Number
- NCT04430036
- Locations
- 🇺🇸
Mays Cancer Center, San Antonio, Texas, United States
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 396
- Registration Number
- NCT04426955
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04405154
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
- Conditions
- Medulloblastoma
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 20
- Registration Number
- NCT04402073
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺Princess Alexandra Hospital - University Of Queensland, Brisbane, Australia
🇦🇺Austin Health - Austin hospital, Melbourne, Australia
d-Limonene +Radiation +Platinum Based Chemo for Xerostomia Prevention in Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Xerostomia
- Interventions
- Drug: D-Limonene GelcapsRadiation: Intensity modulated radiotherapy (IMRT)Drug: CisplatinOther: Xerostomia questionnaire
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 40
- Registration Number
- NCT04392622
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT04390958
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.